Amarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco
December 18 2017 - 4:30PM
Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company
focused on the commercialization and development of therapeutics to
improve cardiovascular health, announced today that John F. Thero,
Amarin's president and chief executive officer, is scheduled to
present a general company update at the 36th Annual J.P. Morgan
Healthcare Conference in San Francisco on Wednesday, January 10,
2018, at 5:00 p.m. PST / 8:00 p.m. EST.
A live audio webcast of the presentation will be
available at: http://www.amarincorp.com, and will be accessible at
the same link for 30 days.
About Amarin
Amarin Corporation plc is a biopharmaceutical
company focused on the commercialization and development of
therapeutics to improve cardiovascular health. Amarin's
product development program leverages its extensive experience in
lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Amarin's clinical program includes a
commitment to an ongoing outcomes study. Vascepa® (icosapent
ethyl), Amarin's first FDA approved product, is a highly-pure,
omega-3 fatty acid product available by prescription. For
more information about Vascepa visit www.vascepa.com. For more
information about Amarin visit www.amarincorp.com.
Availability of other Information about
Amarin
Investors and others should note that Amarin
communicates with its investors and the public using the company
website (www.amarincorp.com), the investor relations website
(http:// investor.amarincorp.com), including but not limited to
investor presentations and investor FAQs, Securities and Exchange
Commission filings, press releases, public conference calls and
webcasts. The information that Amarin posts on these channels
and websites could be deemed to be material information. As a
result, Amarin encourages investors, the media, and others
interested in Amarin to review the information that is posted on
these channels, including the investor relations website, on a
regular basis. This list of channels may be updated from time
to time on Amarin’s investor relations website and may include
social media channels. The contents of Amarin’s website or
these channels, or any other website that may be accessed from its
website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Relations:
Elisabeth Schwartz Investor Relations and Corporate
Communications Amarin Corporation plc In U.S.: +1 (908)
719-1315 investor.relations@amarincorp.com
Lee M. Stern Trout Group In U.S.: +1 (646) 378-2992
lstern@troutgroup.com
Media Inquiries: Ovidio Torres Finn Partners In U.S.: +1
(312) 329-3911 Ovidio.torres@finnpartners.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024